Figure 5
Associations of prophylactic use of nafamostat with the incidence of (a) mild and (b) moderate/severe PIP. RR risks ratios, CI confidence interval, PIP post-endoscopic retrograde cholangiopancreatography pancreatitis.
Figure 5 | Scientific Reports
